US · Healthcare · Biotechnology
Analysts rate Ascentage Pharma Group International a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $44.50.
| Fund | Stake |
|---|---|
| Point72 Asset Management, L.P. | 0.01% |
| Morgan Stanley - Brokerage Accounts | 0.00% |
| Wells Fargo & Co | 0.00% |
| EverSource Wealth Advisors, LLC | 0.00% |
| UBS Group AG | 0.00% |
| BlackRock Inc | 0.00% |
| Royal Bank of Canada | 0.00% |
| Caitong International Asset Management Co., Limited. | 0.00% |
| Document | Date |
|---|---|
| Report of foreign private issuer (6-K) · Q4 2026 HEADLINE NUMBERS • Ascentage Pharma will present data from multiple studies at the 68th ASH Annual Meeting on December 12–15, 2026. • APG-5918’s fir | 2026-11-05 |
| Report of foreign private issuer (6-K) · Q4 2026 OTHER NOTABLE POINTS • Ascentage Pharma Group International filed a Form 6-K with the SEC for October 2026. • On October 27, 2026, the company annou | 2026-10-28 |
| Report of foreign private issuer (6-K) · Q4 2026 OTHER NOTABLE POINTS • Ascentage Pharma Group International filed a Form 6-K with the U.S. Securities and Exchange Commission for October 2026. • On | 2026-10-22 |
| Report of foreign private issuer (6-K) · Q4 2026 HEADLINE NUMBERS • Ascentage Pharma announced that lisafoclax received Breakthrough Therapy Designation in China for treatment-naïve chronic lymphocy | 2026-10-21 |
| Report of foreign private issuer (6-K) · Q4 2026 OTHER NOTABLE POINTS • Ascentage Pharma Group International filed a Form 6-K with the U.S. Securities and Exchange Commission for October 2026. • On | 2026-10-15 |
| Report of foreign private issuer (6-K) · Q3 2026 OTHER NOTABLE POINTS • Ascentage Pharma Group International filed a Form 6-K with the U.S. Securities and Exchange Commission for September 2026. • | 2026-09-29 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Revenue for the six months ended June 30, 2026 was RMB302.2 million (US$44.5 million), up RMB68.5 million, or 29.3% on a constant | 2026-09-17 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Revenue for the six months ended June 30, 2026 was RMB302.2 million (US$44.5 million), up from RMB233.7 million (US$32.6 million) | 2026-08-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ascentage Pharma Group International — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.